Dear Sir,

We hereby describe a case of imatinib-associated gynecomastia. A 40-year-old male, a nonconsumer of alcohol, diagnosed with chronic myeloid leukemia (CML) in chronic phase, was started on tyrosine kinase inhibitor therapy. After 3 months of initiating treatment, he presented with pain in both breasts. There was no history of decreased libido. On examination, he had a 2 cm × 2 cm mobile tender lump in the right breast and 1 cm × 2 cm mobile lump in the left breast \[[Figure 1](#F1){ref-type="fig"}\]. His gonadal and abdominal examinations were normal. Investigations revealed normal renal and liver function tests. Hormonal analysis showed euthyroid status, normal serum testosterone (326 ng/dL), and elevated estradiol level (68 pg/mL). A sonogram of the breasts confirmed gynecomastia on both sides. A final diagnosis of imatinib-associated gynecomastia was made. Gynecomastia is reported to occur in patients with CML or gastrointestinal stromal tumors (GISTs). This effect is probably due to either a reduction in testosterone or due to elevated estradiol levels.\[[@ref1][@ref2]\]
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Imatinib is a kinase inhibitor indicated for the treatment of CML, BCR-ABL-positive acute myeloid leukemia, and metastatic GIST. It is usually well tolerated and has a favorable safety profile. A rare but well-documented effect of imatinib is that it affects male reproductive hormones, leading to a decrease in testosterone production and gynecomastia. Both c-KIT and platelet-derived growth factor receptors (PDGFRs) are expressed in the testes and are involved in organogenesis and synthesis of testosterone. Imatinib inhibits c-KIT and PDGFR, leading to a decrease in testosterone production and gynecomastia.\[[@ref3]\] Gynecomastia has also been reported in males on imatinib therapy for advanced GISTs, in which normal testosterone and elevated estradiol levels were noted.\[[@ref2]\] Tamoxifen is a currently available therapeutic option with which clinical improvement has been reported.\[[@ref2]\] Our patient was offered tamoxifen and is planned to be followed up after 3 months to assess clinical improvement and recovery.
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